Context Therapeutics appoints Dr. Karen Smith and Dr. Luke Walker to Board; board expands to 7 members

Context Therapeutics Inc.

Board size increased from 5 to 7; Dr. Smith (former CMO of Jazz Pharmaceuticals) and Dr. Walker (former CMO of Harpoon Therapeutics) join.
Dr. Smith assigned to Compensation Committee; Dr. Walker to Nominating Committee; both deemed independent under Nasdaq rules.
Each new director received option to purchase 19,315 shares, vesting on earlier of June 13, 2025 or 2025 annual meeting.
Dr. Smith brings over 20 years of oncology drug development (Herceptin, Vyxeos) and regulatory experience; Dr. Walker led Tukysa (tucatinib) development at Seagen.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Karen L. Smith

Director

CNTX · Context Therapeutics Inc.

Effective: 2024-09-04
Filed: September 4, 2024, 7:59 PM ET

On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.

Appointed

Dr. Luke Walker

Director

CNTX · Context Therapeutics Inc.

Effective: 2024-09-04
Filed: September 4, 2024, 7:59 PM ET

On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Karen L. Smith was appointed as Director at Context Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Luke Walker was appointed as Director at Context Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.

View on SEC.gov

Context Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001842952-24-000070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.